Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1

Bortezomib (Velcade) is used widely for the treatment of various human cancers; however, its mechanisms of action are not fully understood, particularly in myeloid malignancies. Bortezomib is a selective and reversible inhibitor of the proteasome. Paradoxically, we find that bortezomib induces prote...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Fang, Jing, Rhyasen, Garrett, Bolanos, Lyndsey, Rasch, Christopher, Varney, Melinda, Wunderlich, Mark, Goyama, Susumu, Jansen, Gerrit, Cloos, Jacqueline, Rigolino, Carmela, Cortelezzi, Agostino, Mulloy, James C., Oliva, Esther N., Cuzzola, Maria, Starczynowski, Daniel T.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2012
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3412348/
https://ncbi.nlm.nih.gov/pubmed/22685174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-02-407999
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg